BioSpace News Archive

FuturaGene and Australia’s CSIRO are pleased to announce that a patent has been issued in Brazil to CSIRO, which covers the downregulation of the expression of plant target genes or other target genes

This brings the total number of markers it simultaneously detects to 27, making Complete::IO™ the most comprehensive flow-cytometry-based biomarker panel in the industry, with a 24-hour turn around time.

ADM Tronics Unlimited today released the following investor update.

This program allows RedHill to provide a discount on EnteraGam directly to eligible patients who are uninsured or underinsured.

Natus management will host an investment-community conference call the same day beginning at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss those results and to answer questions.

Synspira today announced the results of a study exploring poly-N (acetyl, arginyl) glucosamine (PAAG) as a potential new treatment for methicillin-resistant Staphylococcus aureus (MRSA).

Amgen today announced that the Journal of Clinical Oncology published positive overall survival findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone reduced the risk of death by 21 percent versus lenalidomide and dexamethasone alone and extended OS by 7.9 months in patients with relapsed or refractory multiple myeloma.

Data added to the label demonstrated that KYPROLIS and dexamethasone (Kd) reduced the risk of death by 21 percent and increased OS by 7.6 months versus Velcade (bortezomib) and dexamethasone (Vd).

Arrowhead today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement.

In today’s decision, the PTO concluded that Argentum “satisfied its burden of demonstrating, by a preponderance of the evidence, that the subject matter of claims 1-20 would have been obvious,” and therefore ordered “that claims 1-20 are held unpatentable.”